Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Mecillinam resistance and outcome of pivmecillinam treatment in uncomplicated lower urinary tract infection in women.

Monsen TJ, Holm SE, Ferry BM, Ferry SA.

APMIS. 2014 Apr;122(4):317-23. doi: 10.1111/apm.12147.

PMID:
24738161
3.

Pivmecillinam in treatment of Staphylococcus saprophyticus urinary tract infections.

Granlund M, Landgren E, Henning C.

Scand J Infect Dis. 1983;15(1):65-9.

PMID:
6302831
4.

[Urinary tract pathogens in uncomplicated lower urinary tract infections in women in Norway].

Jureen R, Digranes A, Baerheim A.

Tidsskr Nor Laegeforen. 2003 Aug 14;123(15):2021-2. Norwegian.

5.

Nalidixic acid and pivmecillinam for treatment of acute lower urinary tract infections.

Hovelius B, Mårdh PA, Nygaard-Pedersen L, Wathne B.

Scand J Prim Health Care. 1985 Nov;3(4):227-32.

PMID:
4081404
6.

Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.

Jansåker F, Frimodt-Møller N, Sjögren I, Dahl Knudsen J.

J Antimicrob Chemother. 2014 Mar;69(3):769-72. doi: 10.1093/jac/dkt404. Epub 2013 Oct 9.

PMID:
24107388
7.

Pivmecillinam--therapy of choice for lower urinary tract infection.

Graninger W.

Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:73-8. Review.

PMID:
14527775
8.
9.

[Prescriptions of a new antibiotic following treatment with sulfamethizole or pivmecillinam].

Bjerrum L, Dessau RB, Hallas J.

Ugeskr Laeger. 2003 Sep 22;165(39):3732-5. Swedish. No abstract available.

PMID:
14558387
10.

Microflora changes with norfloxacin and pivmecillinam in women with recurrent urinary tract infection.

Norinder BS, Norrby R, Palmgren AC, Hollenberg S, Eriksson U, Nord CE.

Antimicrob Agents Chemother. 2006 Apr;50(4):1528-30.

11.

Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial.

Bjerrum L, Gahrn-Hansen B, Grinsted P.

Scand J Prim Health Care. 2009;27(1):6-11. doi: 10.1080/02813430802535312.

12.
13.

Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.

Lampri N, Galani I, Poulakou G, Katsarolis I, Petrikkos G, Giamarellou H, Souli M.

J Antimicrob Chemother. 2012 Oct;67(10):2424-8. doi: 10.1093/jac/dks215. Epub 2012 Jun 4.

PMID:
22665388
14.
15.

Resistance profiles of urinary tract infections in general practice--an observational study.

Schmiemann G, Gágyor I, Hummers-Pradier E, Bleidorn J.

BMC Urol. 2012 Nov 21;12:33. doi: 10.1186/1471-2490-12-33.

16.
18.

Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection.

Menday AP.

Int J Antimicrob Agents. 2000 Jan;13(3):183-7.

PMID:
10724022
19.

Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).

Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Palatnik LP, Johnson J, Noreddin A, Harding GK, Nicolle LE, Hoban DJ; NAUTICA Group..

Int J Antimicrob Agents. 2005 Nov;26(5):380-8.

PMID:
16243229
20.

Supplemental Content

Support Center